The pharmacokinetics of cefamandole were studied in four patients with stable renal failure, two patients undergoing peritoneal dialysis, and four patients undergoing hemodialysis. Peak concentrations of cefamandole in serum were achieved 1 to 2 h after intramuscular injection in the patients with stable renal impairment, and the concentrations declined slowly, with half-life values of 12.3 to 18 h. Cefamandole was removed only very slowly by peritoneal dialysis. Hemodialysis was more efficient in removing cefamandole, with serum half-life values ranging from 3.8 to 7.9 h. The mean apparent volume of distribution of cefamandole in these 10 patients was 21.92 liters, or 31% of the body weight.
Cefamandole, a new cephalosporin derivative, has a broad spectrum of antimicrobial activity against gram-positive and gram-negative bacteria, including Haemophilus influenzae (3, 9, 11) . Pharmacokinetic studies in healthy human volunteers have shown that excellent concentrations of cefamandole in serum are achieved after both intramuscular and intravenous injections (10) . Recent clinical studies have demonstrated that cefamandole is an effective agent for the treatment of seriously ill hospitalized patients with a variety of infections due to gram-positive and gram-negative bacteria (B. R. Meyers, P. Nicholas, and S. Z. Hirschman, manuscript in preparation). In this report we present results of pharmacokinetic studies with cefamandole in patients with stable renal failure and in patients undergoing peritoneal dialysis and hemodialysis.
MATERIALS AND METHODS
Four patients with stable renal failure, two patients undergoing peritoneal dialysis, and four patients requiring hemodialysis were the subjects of this study. Each patient received 1 g of cefamandole intramuscularly. Serum samples were collected from the patients with stable renal failure before injection and at timed intervals postinjection. Dialysate samples were collected from patients undergoing dialysis. Peritoneal dialysis with a solution containing sodium chloride, calcium chloride, magnesium chloride, sodium lactate, and dextrose (InperSol) was begun 1 h after the injection ofcefamandole.
All dialysis runs lasted 45 to 60 min, and each patient was treated for 36 exchanges. Patients undergoing hemodialysis were placed on a Travenol coil hemodialysis machine for 6 h at 1 h after the intramuscular administration of cefamandole.
Serum, urine, and dialysate samples were stored at -70°C. The concentration of cefamandole in the various specimens was determined by the cup-plate method, using Bacillus subtilis as the test organism as previously described (10) . The regression lines of the logs of the concentrations of cefamandole in serum versus time and their correlation coefficients (r) were calculated by the method of least squares, using a standard computer program to obtain the half-life (t112) of the drug in each patient. These calculations were based on a one-compartment model for the pharmacokinetics of the drug (4). The apparent volume of distribution (AVD) of cefamandole was calculated from the formula AVD = I/Co, where I is the intramuscular dose in milligrams and CO is the expected serum concentration at the time of injection, assuming rapid equilibration (2). The CO was obtained by extrapolation of the regression lines of the log concentration of cefamandole in serum versus time (2) .
All patients signed certificates of informed consent for the studies according to institutional policy.
RESULTS
Four patients with stable renal impairment and serum creatinine concentrations ranging from 5 to 9 mg/100 ml were studied (Table 1) . Peak concentrations of cefamandole in serum were achieved between 1 and 2 h after intramuscular injection. The serum concentration declined slowly, and drug levels still could be measured at 72 h. The serum tl2 of cefamandole ranged from 12.3 to 18 h and was greater in patients with higher serum creatinine concentrations ( (Table 2 ). Both patients still had a concentration of 10 ,ug of cefamandole per ml in their serum at 30 h. The average serum tl2 during peritoneal dialysis was 11.8 h. The mean dialysate concentration of cefamandole was 4.82 ,tg/ ml; a peak concentration of 19 ,g/ml was obtained 2 h after injection.
Four patients were given cefamandole before hemodialysis. The serum creatinine in these four patients ranged from 7.1 to 14.8 mg/100 ml (Table 3) . Cefamandole was removed to a greater extent during hemodialysis than during peritoneal dialysis; the serum tl2 values ranged from 3.8 to 7.9 h during the 6-h dialysis period (Table 3) .
The mean AVD for the 10 patients in this study was 21.92 ± 10.27 (standard deviation) liters, or 31% of the body weight.
DISCUSSION
In patients with normal renal function cefamandole is excreted primarily by the kidneys (10) . The serum t1,2 after intramuscular adininistration of cefamandole to human volunteers with normal renal function was 1.17 h, and the AVD was 17.11 liters, or 24% ofthe body weight (10) . The serum tl2 of cefamandole in patients with stable renal impairment and serum creatinine values .5 mg/100 ml was approximately 10 to 15 times greater than that obtained in volunteers with normal renal function. The tl,2 was greater in patients with higher serum cre- atinine values as has been observed with other cephalosporin derivatives (1, 8) . The mean AVD of 21.92 liters in the group of 10 patients with renal failure was higher than that of 17.11 liters found in healthy volunteers. However, the range of values in the ten patients (13.2 to 41 liters) was great and may reflect a poor absorption of the drug after intramuscular injection in the sicker patients, such as those with severe congestive heart failure.
Peritoneal dialysis removed cefamandole at a very slow rate. The serum t1/2 in the two patients studied was still markedly prolonged. The average dialysate concentration of cefamandole of 4.8 ,ug/ml was above the minimum inhibitory concentrations of the drug for suceptible gram-positive bacteria and also for many susceptible gram-negative bacteria (9) . Hemodialysis was more efficient in removing cefamandole than was peritoneal dialysis, yet the serum t1,2 values were still much greater than those observed in patients with normal renal function.
The effects of peritoneal dialysis and hemodialysis on the removal of other cephalosporins have been studied and can be compared with the results reported here for cefamandole. Perkins et al. (12) found a 24% reduction of mean peak concentrations of both cephalothin and cephaloridine in serum during peritoneal dialysis below those observed in a base line study.
The serum tl2 values ofthe drugs during peritoneal dialysis were about 10 to 12 h. After 1-g intramuscular doses serum cephalothin concentrations fell to 0 at 48 h with peritoneal dialysis, but cephaloridine was still detectable at 72 h. Cephaloridine is significantly removed from blood by hemodialysis (10) . Hemodialysis of patients with creatinine clearances c5 ml/min lowered the serum t1/2 of cefazolin, a cephalosporin derivative highly bound to protein, from 56.6 to 8.8 h; peritoneal dialysis had little effect on the tl2 (6) . McCloskey et al. (8) reported that hemodialysis removed 23% of an administered dose of cephapirin during a 6-h dialysis period. Linquist et al. (7) showed that the tl2 of cephalexin, an orally administered cephalosporin, was decreased from 30.8 to 6.3 h in patients with renal failure undergoing hemodialysis. Thus, cefamandole is similar to other cephalosporin derivatives in the marked prolongation of serum t12 in patients with renal failure, the very slow removal of drug during peritoneal dialysis, and the more efficient removal during hemodialysis. As suggested for other cephalosporins in patients with renal failure (6), it would appear that a loading dose of cefamandole followed by one-third to one-half of the loading dose every tl2 would be sufficient dosage. This dosage would also apply to patients undergoing peritoneal dialysis. In patients undergoing hemodialysis, an additional one-third to one-half of the loading dose should be administered at the end of the dialysis. When possible, levels of cefamandole in serum should be measured, at least initially, to correctly adjust the dosage.
